Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

K. Shidahara, K. Hayashi, Kenei Sada, S. Hiramatsu, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, T. Kawabata, Jun Wada

Research output: Contribution to journalArticle

Abstract

We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

Original languageEnglish
Pages (from-to)1374-1377
Number of pages4
JournalLupus
Volume27
Issue number8
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Neuromyelitis Optica
Systemic Lupus Erythematosus
Aquaporin 4
Antibodies
Optic Nerve
Rituximab
Therapeutics

Keywords

  • Anti-aquaporin-4 antibody
  • neuromyelitis optica
  • rituximab
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab. / Shidahara, K.; Hayashi, K.; Sada, Kenei; Hiramatsu, S.; Morishita, Michiko; Watanabe, Haruki; Matsumoto, Yoshinori; Kawabata, T.; Wada, Jun.

In: Lupus, Vol. 27, No. 8, 01.07.2018, p. 1374-1377.

Research output: Contribution to journalArticle

@article{1e582bffe02f467e97602168e652ecc4,
title = "Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab",
abstract = "We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.",
keywords = "Anti-aquaporin-4 antibody, neuromyelitis optica, rituximab, systemic lupus erythematosus",
author = "K. Shidahara and K. Hayashi and Kenei Sada and S. Hiramatsu and Michiko Morishita and Haruki Watanabe and Yoshinori Matsumoto and T. Kawabata and Jun Wada",
year = "2018",
month = "7",
day = "1",
doi = "10.1177/0961203318760994",
language = "English",
volume = "27",
pages = "1374--1377",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

AU - Shidahara, K.

AU - Hayashi, K.

AU - Sada, Kenei

AU - Hiramatsu, S.

AU - Morishita, Michiko

AU - Watanabe, Haruki

AU - Matsumoto, Yoshinori

AU - Kawabata, T.

AU - Wada, Jun

PY - 2018/7/1

Y1 - 2018/7/1

N2 - We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

AB - We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

KW - Anti-aquaporin-4 antibody

KW - neuromyelitis optica

KW - rituximab

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85048002303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048002303&partnerID=8YFLogxK

U2 - 10.1177/0961203318760994

DO - 10.1177/0961203318760994

M3 - Article

C2 - 29498304

AN - SCOPUS:85048002303

VL - 27

SP - 1374

EP - 1377

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 8

ER -